Cargando…

Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis

Rheumatoid factor (RF) is currently used in the diagnosis of rheumatoid arthritis (RA). The discovery of anticitrullinated protein autoantibodies has led to the development of various new tests, such as anti-cyclic citrullinated peptide (anti-CCP) antibodies, and anti-mutated citrullinated vimentin...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shukaili, Ahmed, Al-Ghafri, Saif, Al-Marhoobi, Safia, Alkaabi, Juma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426236/
https://www.ncbi.nlm.nih.gov/pubmed/22934118
http://dx.doi.org/10.1155/2012/285854
_version_ 1782241484865536000
author Al-Shukaili, Ahmed
Al-Ghafri, Saif
Al-Marhoobi, Safia
Alkaabi, Juma
author_facet Al-Shukaili, Ahmed
Al-Ghafri, Saif
Al-Marhoobi, Safia
Alkaabi, Juma
author_sort Al-Shukaili, Ahmed
collection PubMed
description Rheumatoid factor (RF) is currently used in the diagnosis of rheumatoid arthritis (RA). The discovery of anticitrullinated protein autoantibodies has led to the development of various new tests, such as anti-cyclic citrullinated peptide (anti-CCP) antibodies, and anti-mutated citrullinated vimentin (anti-MCV) antibodies, to diagnose RA. The aims of this study were to determine the sensitivity and specificity of anti-MCV antibodies in comparison with anti-CCP antibodies and RF in Omani Arab patients with RA and compare our findings with published values from different ethnic groups. The sensitivity of anti-MCV antibodies was 72% with 87% specificity. For anti-CCP antibodies the sensitivity was 52% and the specificity was 97%. The sensitivity of RF was 57% with 94% specificity. Anti-CCP antibodies have higher diagnostic specificity and positive predictive value than RF and anti-MCV antibodies. Anti-MCV antibodies have the highest sensitivity when compared to anti-CCP antibodies and RF. Anti-MCV antibodies do not appear to be very useful in the diagnosis of RA. However, long-term study is required to find out whether anti-MCV antibodies can be used as predictive test for incidence of RA.
format Online
Article
Text
id pubmed-3426236
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34262362012-08-29 Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis Al-Shukaili, Ahmed Al-Ghafri, Saif Al-Marhoobi, Safia Alkaabi, Juma Int J Rheumatol Clinical Study Rheumatoid factor (RF) is currently used in the diagnosis of rheumatoid arthritis (RA). The discovery of anticitrullinated protein autoantibodies has led to the development of various new tests, such as anti-cyclic citrullinated peptide (anti-CCP) antibodies, and anti-mutated citrullinated vimentin (anti-MCV) antibodies, to diagnose RA. The aims of this study were to determine the sensitivity and specificity of anti-MCV antibodies in comparison with anti-CCP antibodies and RF in Omani Arab patients with RA and compare our findings with published values from different ethnic groups. The sensitivity of anti-MCV antibodies was 72% with 87% specificity. For anti-CCP antibodies the sensitivity was 52% and the specificity was 97%. The sensitivity of RF was 57% with 94% specificity. Anti-CCP antibodies have higher diagnostic specificity and positive predictive value than RF and anti-MCV antibodies. Anti-MCV antibodies have the highest sensitivity when compared to anti-CCP antibodies and RF. Anti-MCV antibodies do not appear to be very useful in the diagnosis of RA. However, long-term study is required to find out whether anti-MCV antibodies can be used as predictive test for incidence of RA. Hindawi Publishing Corporation 2012 2012-08-15 /pmc/articles/PMC3426236/ /pubmed/22934118 http://dx.doi.org/10.1155/2012/285854 Text en Copyright © 2012 Ahmed Al-Shukaili et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Al-Shukaili, Ahmed
Al-Ghafri, Saif
Al-Marhoobi, Safia
Alkaabi, Juma
Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
title Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
title_full Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
title_fullStr Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
title_full_unstemmed Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
title_short Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
title_sort evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in omani patients with rheumatoid arthritis
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426236/
https://www.ncbi.nlm.nih.gov/pubmed/22934118
http://dx.doi.org/10.1155/2012/285854
work_keys_str_mv AT alshukailiahmed evaluationofantimutatedcitrullinatedvimentinantibodiesanticycliccitrullinatedpeptideantibodiesandrheumatoidfactorinomanipatientswithrheumatoidarthritis
AT alghafrisaif evaluationofantimutatedcitrullinatedvimentinantibodiesanticycliccitrullinatedpeptideantibodiesandrheumatoidfactorinomanipatientswithrheumatoidarthritis
AT almarhoobisafia evaluationofantimutatedcitrullinatedvimentinantibodiesanticycliccitrullinatedpeptideantibodiesandrheumatoidfactorinomanipatientswithrheumatoidarthritis
AT alkaabijuma evaluationofantimutatedcitrullinatedvimentinantibodiesanticycliccitrullinatedpeptideantibodiesandrheumatoidfactorinomanipatientswithrheumatoidarthritis